一名使用醋酸格拉替雷和格拉替雷仿制药Glatopa治疗多发性硬化症的患者发生淋巴瘤样丘疹病：病例报告
Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report.
作者信息
Shirani Afsaneh, Dalton Scott R, Avery Eric J, Arcot Jayagopal Lakshman, Meyer Christina, Stuve Olaf, Zabad Rana
机构信息
Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
Sagis Dermatopathology, Houston, TX, USA.
出版信息
J Cent Nerv Syst Dis. 2021 Nov 20;13:11795735211053784. doi: 10.1177/11795735211053784. eCollection 2021.
A 48-year-old Caucasian woman with history of multiple sclerosis (MS) presented with erythematous papulonodular lesions in her extremities and trunk. She was being treated with glatiramer acetate (GA) for the past 10 years and the glatiramoid, Glatopa, for 2 years prior to this presentation. A skin biopsy showed CD30 lymphoproliferative disorder consistent with lymphomatoid papulosis (LyP). Three weeks after stopping Glatopa, her skin lesions were improved. It remains unclear whether GA's or Glatopa's capability to alter T-cell differentiation, may have a link with LyP. This case report is a reminder to be vigilant for skin lesions in patients with MS.
一名患有多发性硬化症（MS）的48岁白人女性，其四肢和躯干出现了红斑性丘疹结节性病变。在过去10年里她一直在接受醋酸格拉替雷（GA）治疗，在此次就诊前2年使用的是格拉替雷类似物Glatopa。皮肤活检显示CD30淋巴细胞增殖性疾病，符合淋巴瘤样丘疹病（LyP）。停用Glatopa三周后，她的皮肤病变有所改善。目前尚不清楚GA或Glatopa改变T细胞分化的能力是否可能与LyP有关。本病例报告提醒人们要对MS患者的皮肤病变保持警惕。
Zotero 插件